Outlook Therapeutics® to Present at the Retina World Congress 2024
02 mai 2024 09h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
29 avr. 2024 09h00 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
15 avr. 2024 16h15 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
22 mars 2024 07h35 HE
|
Outlook Therapeutics, Inc.
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook...
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
18 mars 2024 17h10 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
12 mars 2024 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic...
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
14 févr. 2024 08h05 HE
|
Outlook Therapeutics, Inc.
NORSE EIGHT underway with first subject dosed and additional clinical sites beginning enrollment Continue to expect planned resubmission of the ONS-5010 Biologics License Application (BLA) by the end...
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
31 janv. 2024 08h05 HE
|
Outlook Therapeutics, Inc.
NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Biologics License Application (BLA) by the end of...
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
23 janv. 2024 08h00 HE
|
Outlook Therapeutics, Inc.
Obtained clarity from U.S. Food and Drug Administration (FDA) on next steps to advance ONS-5010NORSE EIGHT expected to commence in the first quarter of CY2024, enabling potential resubmission of the...
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
22 déc. 2023 08h05 HE
|
Outlook Therapeutics, Inc.
Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024Company reaffirms potential for European approval for ONS-5010 with Marketing Authorization Application...